Harvard Bioscience (HBIO) EBITDA (2010 - 2026)
Harvard Bioscience (HBIO) EBITDA from Jun 30, 2010 to Mar 31, 2026. The TTM Harvard Bioscience (HBIO) EBITDA is $1.66M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Harvard Bioscience (HBIO) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 3 Years TTM | -17.25% |
| 5 Years TTM | -20.26% |
| 10 Years TTM | +5.41% |
| All Time TTM | -8.56% |
Annual EBITDA change of Harvard Bioscience (HBIO)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$730K | -98.44% |
| 2025 | -$47M | +945.54% |
| 2024 | -$4.48M | -232.94% |
| 2023 | $3.37M | -161.50% |
| 2022 | -$5.48M | -242.34% |
| 2021 | $3.85M | +79.91% |
| 2020 | $2.14M | -40.88% |
| 2019 | $3.62M | +6.16% |
| 2018 | $3.41M | +401.47% |
| 2017 | $680K | -146.58% |
| 2016 | -$1.46M | -4966.67% |
| 2015 | $30K | -99.62% |
| 2014 | $7.87M | +177.11% |
| 2013 | $2.84M | -76.41% |
| 2012 | $12M | -5.42% |
| 2011 | $13M | -9.97% |
| 2010 | $14M | +52.70% |
| 2009 | $9.26M | N/A |
Comparison Harvard Bioscience (HBIO) five years EBITDA CAGR with competitors
Harvard Bioscience (HBIO) five years EBITDA CAGR is -20.33%.